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A B S T R A C T
Phenylketonuria (PKU) is a recessive disorder characterized by disruption in the metabolism of the amino acid
phenylalanine (Phe). Prior research indicates that individuals with PKU have substantial white matter (WM)
compromise. Much less is known about gray matter (GM) in PKU, but a small body of research suggests volu-
metric differences compared to controls. To date, developmental trajectories of GM structure in individuals with
PKU have not been examined, nor have trajectories of WM and GM been examined within a single study. To
address this gap in the literature, we compared longitudinal brain development over a three-year period in
individuals with PKU (n = 35; 18 male) and typically-developing controls (n = 71; 35 male) aged 7–21 years.
Using diffusion tensor imaging (DTI) and structural magnetic resonance imaging (MRI), we observed whole-
brain and regional WM differences between individuals with PKU and controls, which were often exacerbated
with increasing age. In marked contrast with trajectories of WM development, trajectories of GM development
did not differ between individuals with PKU and controls, indicating that neuropathology in PKU is more pro-
minent in WM than GM. Within individuals with PKU, mediation analyses revealed that whole-brain mean
diffusivity (MD) and regional MD in the corpus callosum and centrum semiovale mediated the relationship
between dietary treatment compliance (i.e., Phe control) and executive abilities, suggesting a plausible neuro-
biological mechanism by which Phe control may influence cognitive outcomes. Our findings clarify the speci-
ficity, timing, and cognitive consequences of whole-brain and regional WM pathology, with implications for
treatment and research in PKU.
1. Introduction
Phenylketonuria (PKU; OMIM212600) is an autosomal recessive dis-
order characterized by an error in the metabolism of the amino acid phe-
nylalanine (Phe) (Dyer, 1999). Deficiency in or absence of the phenylala-
nine hydroxylase enzyme (PAH; EC # 1.14.16.1) results in decreased
tyrosine (a precursor to catecholaminergic neurotransmitters) and accu-
mulation of Phe at substantially higher than normal levels in blood and
tissue (Scriver, 2007). PKU occurs in all ethnic groups (Hardelid et al.,
2008), with an estimated worldwide prevalence of 1 in 10,000 live births
(Waters et al., 2018). When untreated, the neurotoxic accumulation of Phe
results in severe intellectual disability (Anderson et al., 2007). However, the
most serious cognitive sequelae are now generally avoided through early
detection and dietary treatment to limit Phe intake (Waisbren et al., 2007).
Notwithstanding, individuals with early-and continuously-treated PKU ex-
perience neuropsychological impairment (Araujo et al., 2009; Banerjee
et al., 2011; Christ et al., 2006; Hawks et al., 2018; Janos et al., 2012),
particularly related to executive abilities (Christ et al., 2010; Jahja et al.,
2017).
The neurobiological underpinnings of executive dysfunction in PKU
are incompletely understood, although white matter (WM) compromise
appears to play an important role (Anderson et al., 2007; Hood et al.,
2016, 2015). Gross WM abnormalities, assessed through visual in-
spection of structural magnetic resonance images (MRI), have long been
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noted in some individuals with PKU (Christ et al., 2010; Das et al.,
2013; Leuzzi et al., 2007, 1993; Manara et al., 2009; Rupp et al., 2001;
Scarabino et al., 2009; Thompson et al., 1993). More recently, diffusion
tensor imaging (DTI) has been used to study microstructural WM in-
tegrity in PKU. DTI studies have identified restricted diffusivity in in-
dividuals with PKU across a number of brain regions, including the
centrum semiovale, posterior-parietal occipital cortex, prefrontal
cortex, optic radiation, putamen, and anterior corpus callosum
(Antenor-Dorsey et al., 2013; Christ et al., 2010; Ding et al., 2008; Kono
et al., 2005; Peng et al., 2013; Vermathen et al., 2007; White et al.,
2013, 2010). Tract based spatial statistics (TBSS) provide convergent
evidence for widespread WM compromise in PKU (Antenor-Dorsey
et al., 2013; Hawks et al., 2017; Hood et al., 2015).
In contrast, much less is known about gray matter (GM) in PKU. A
small body of exploratory research suggests that GM volume may differ
between individuals with PKU and neurotypical controls, but the di-
rectionality of such effects is unclear. PKU has been associated with
decreased GM volume in the parietal lobe, occipital lobe, pons, hip-
pocampus, thalamus, caudate nucleus, and nucleus accumbens (Bodner
et al., 2012; Christ et al., 2016; Pérez-Dueñas et al., 2006; Pfaendner
et al., 2005). PKU has also been associated with increased brain volume
in putamen and the ventral striatum (Bodner et al., 2012; Pérez-Dueñas
et al., 2006). Confoundingly, the nucleus accumbens is a substructure of
the ventral striatum, yet these regions exhibited opposing group effects
(i.e., decreased volume in PKU relative to controls in the nucleus ac-
cumbens; increased volume in PKU relative to controls in the ventral
striatum). Recent research examining the role of biogenic amines in
PKU found a negative correlation between cerebrospinal Phe levels and
frontotemporal GM volume, supporting the need for continued Phe
control during adulthood to mitigate age-related brain atrophy (Pilotto
et al., 2019). Taken together, results strongly motivate further research
to elucidate patterns of GM development in PKU.
Moving beyond group differences, little is known regarding the
trajectories of WM and GM development in PKU. Likely due to chal-
lenges associated with data collection in rare disorders, there have been
only two longitudinal studies of brain development in PKU, and both of
these studies assessed only WM pathology (Mastrangelo et al., 2015;
Nardecchia et al., 2015). Nardecchia et al. found that participants with
PKU exhibited normal-appearing WM in early adolescence but WM
abnormalities in early adulthood. Relatedly, Mastrangelo et al. retro-
spectively analyzed serial MRIs from individuals with PKU aged 12 to
37 years and found that the frequency and severity of WM abnormal-
ities increased with age. Of note, these studies used clinician-rated se-
verity scores to describe gross WM abnormalities rather than highly-
sensitive DTI approaches.
Methodological differences, small samples sizes, limited longitudinal
follow-up, and differing participant characteristics within and across pre-
vious studies have hindered attempts to characterize WM and GM devel-
opment in PKU. We aimed to fill this gap in the literature. To examine WM
and GM developmental trajectories, we analyzed DTI and structural MRI
data from individuals with PKU and age-matched typically-developing
controls. Data were collected at three timepoints over approximately three
years. In addition, to determine how the interplay between elevated Phe
and WM and GM pathology may influence cognitive outcomes in in-
dividuals with PKU, we conducted mediation analyses within our PKU
sample. Our study represents the first longitudinal examination of GM in
PKU and the first examination of WM and GM within a single sample of
individuals with PKU, thereby clarifying the specificity, timing, and cogni-
tive consequences of neural compromise in PKU.
2. Materials and methods
2.1. Participants
Participants with early-and continuously-treated classic PKU
(n = 35; 18 males, 17 females) were recruited through metabolic clinics
at Washington University in St. Louis (WUSTL) and Oregon Health &
Science University (OHSU) (Table 1). All participants were diagnosed in
early infancy via newborn screening (Phe > 360 μmol/L) and there-
after placed on restricted Phe diets. The great majority of participants
had genetic confirmation of the PAH defect (although not all due to
insurance payment denials). Lifetime mean Phe prior to study baseline
ranged from 161.1 to 979.8 μmol/L (mean = 399.3, SD = 182.9), and
lifetime Phe variability prior to study baseline, measured in standard
deviation units, ranged from 75.2 to 452.0 (mean = 217.7,
SD = 100.1). WM and GM development in participants with PKU was
compared to that of typically developing controls (n = 71; 35 males, 36
females) recruited from St. Louis, Missouri and Portland, Oregon
communities. Given our developmental focus, participants were ex-
cluded if age at study baseline exceeded 25 years. Participants were also
excluded if they reported a history of major medical, psychiatric, or
learning disorder unrelated to PKU.
2.2. Procedure
Approval for this study was obtained from the institutional review
boards at WUSTL and OHSU. Written informed consent was obtained
from all participants and/or legal guardians prior to data collection.
Referring metabolic clinics provided blood Phe levels over the lifetime
based on available medical records. Cognitive and neuroimaging data
were collected at each of the three longitudinal timepoints during a
session lasting approximately 4 h. The average time elapsed between
timepoints 1 and 2 was 1.5 (SD = 0.18, range = 1.3–2.0) years for
participants with PKU and 1.6 (SD = 0.12, range = 1.3–1.8) years for
controls. The average time elapsed between timepoints 2 and 3 was 1.6
(SD = 0.21, range = 1.1–2.0) years for participants with PKU and 1.5
(SD = 0.14, range = 1.2–1.8) years for controls. Analyses included a
total of 196 MRI scans from 35 participants with PKU and 71 controls.
Thirty-six participants (14 PKU, 22 control) were scanned twice, and 27
participants (6 PKU, 21 Control) were scanned three times. Some cross-
sectional WM and cognitive data reported here were used in previous
reports (Hawks et al., 2018; Hood et al., 2016), but findings related to
GM and longitudinal trajectories of WM have not been reported pre-
viously.
2.3. Imaging data acquisition
Neuroimaging procedures are described in detail by Hood et al.
(2016). Briefly, scans were run on a 3.0 T Siemens Trio at OHSU and
1.5 T Siemens Sonata at WUSTL. Structural MRI data included a T1-
weighted magnetization prepared rapid acquisition gradient echo
Table 1




Timepoint 1 54 27
Timepoint 2 45 12
Timepoint 3 36 22
Mean (SD) Range Mean (SD) Range
Age (years)
Timepoint 1 12.5 (3.5) 7–19 13.0 (4.0) 7–19
Timepoint 2 13 (2.8) 9–19 14.6 (3.5) 10–20
Timepoint 3 14.3 (3.1) 10–21 14.7 (3.5) 10–21
WASI Standard Score
IQ 115.1 (15.1) 82–143 107.7 (11.0) 86–139
Notes: Controls and participants with PKU were lost to follow-up after time-
points 1 and 2 due to inability to contact, study withdrawal, or failure to attend
appointments. SD = standard deviation; WASI = Weschler Abbreviated Scale
of Intelligence; IQ = intelligence quotient; WASI scores reflect Timepoint 1
measurements.
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sequence [TR = 1580 ms, TE = 3.93 ms, inversion time of 1000 ms,
with isotropic 1.0 × 1.0 × 1.0 mm3 voxels] and a fast spin echo T2-
weighted sequence [TR = 3500 ms, TE = 106 ms, with isotropic
1.0 × 1.0 × 2.0 mm3 voxels]. DTI data were collected using an echo
planar imaging (EPI) sequence acquired 4 times for each participant
[TR = 9000 ms, TE = 84 ms (OHSU) and 78 ms (WUSTL), 2.5 mm3
(OSHU) and 3.0 mm3 (WUSTL) isotropic voxels, conventional 6 direc-
tion encoding with diffusion sensitization of b-values = 0 and 1000 s/
mm2]. Total imaging time was approximately 1 h. Due to neuroimaging
acquisition complications at OHSU at timepoint 2, MR images from a
subset of participants showed poor contrast, necessitating additional
exclusions prior to analyses (n = 16; 8 controls, 8 PKU). Available data
from these participants at timepoints 1 and 3 were retained.
2.3.1. WM data processing
Four complete DTI datasets were acquired for each participant and
were concatenated for the analysis. Diffusion weighted images were
registered first to the b = 0 unsensitized image, then to the T2W, then
to the best T1W (MPRAGE), and finally to an in-house atlas at WUSTL.
Parametric maps were generated for mean diffusivity (MD), axial dif-
fusivity (AD), radial diffusivity (RD), and fractional anisotropy (FA).
Whole-brain measures of MD, AD, RD, and FA were computed for each
participant by averaging each DTI parameter across the entire WM
skeleton using the TBSS method (Smith et al., 2007). Additionally, re-
gion of interest (ROI) analyses were used to compare MD between study
groups. ROIs were determined using a well-established DTI atlas (Oishi
et al., 2008) and verified by a radiologist.
2.3.2. GM data processing
Structural magnetic resonance imaging (MRI) processing and ana-
lyses were implemented in FreeSurfer 5.3.0 (https://surfer.nmr.mgh.
harvard.edu/) (Fischl, 2012) using the WUSTL Center for High Per-
formance Computing cluster. FreeSurfer was used to parcellate and
segment individual participants' anatomical MPRAGE scans at each
timepoint in native (non-atlas) space, enabling computation of struc-
tural properties for downstream analyses.
Given our concern that neuropathology in PKU might influence
automatic segmentation in FreeSurfer, additional attention was taken to
ensure data quality. All FreeSurfer segmentations were reviewed for
errors (e.g., WM exclusions and dura inclusions) by trained research
assistants blinded to participant factors (e.g., group status, age, gender).
Errors were manually edited using control points, and edited volumes
were reprocessed through the FreeSurfer processing pipeline. Brain
volumes were reprocessed up to a maximum of three times, at which
point they were excluded from analyses if they did not meet quality
control standards. Authors ZH and AH were trained in Human
Connectome Project quality control procedures (Marcus et al., 2013)
and made final, blinded determinations about data inclusion and ex-
clusion. Exclusions were made at the level of observations (i.e., time-
points) rather than participants. 43 of 239 observations (18%) were
excluded prior to analyses due to poor segmentation quality. Corre-
sponding observations were excluded from the DTI dataset to facilitate
contrasts between WM and GM.
After data quality was verified, FreeSurfer-generated estimates of
GM volume, cortical GM volume, surface area, and cortical thickness
were extracted for whole-brain analyses and summed (GM volume,
cortical GM volume, surface area) or averaged (cortical thickness)
across hemispheres. Additionally, FreeSurfer-generated estimates of
volume in the dorsolateral prefrontal cortex (DLPFC), insula, caudate
nucleus, putamen, nucleus accumbens, precuneus, supramarginal
gyrus, superior parietal lobule, inferior occipital gyrus, posterior
transverse collateral sulcus, and parieto-occipital sulcus were extracted
for ROI analyses using the Destrieux atlas and summed across hemi-
spheres (Destrieux et al., 2010).
2.4. Index of Phe control
Given that older participants with PKU have accrued longer ex-
posure to elevated Phe compared to younger participants with PKU, we
selected mean Phe exposure over the lifetime as our index of Phe
control (Hood et al., 2015). This index was based on prior literature
modeling exposure to hyperglycemia and hypoglycemia in children
with diabetes (Perantie et al., 2007). Like diabetes, PKU is a chronic
metabolic illness in which poor dietary management is associated with
neural and cognitive consequences (Nardecchia et al., 2015; National
Institutes of Health Consensus Development, 2001).
To calculate lifetime Phe exposure, standard (z) scores for lifetime
mean Phe and age were computed for each participant based on means
and standard deviations of the sample. Lifetime Phe exposure for each
participant was then calculated by summing z scores for lifetime Phe
and age, producing an approximately normal distribution
(mean = 0.15, range = −2.75 to 5.19) where higher scores were in-
dicative of greater exposure. As expected, due to the positive correla-
tion between Phe levels and age, distributional spread was slightly
wider than normal (SD = 1.85).
2.5. Executive abilities
An executive abilities composite was created by summing standar-
dized (z) scores from tests of non-verbal strategic processing, verbal
strategic processing, and working memory (described in detail in Hood
et al., 2016 and Janos et al., 2012). The executive abilities tasks were
selected because they have been shown to differentiate participants
with PKU from controls (Antenor-Dorsey et al., 2013; DeRoche and
Welsh, 2008; Hawks et al., 2017). Briefly, non-verbal strategic proces-
sing was assessed using the Matrix Reasoning subtest from the Wechsler
Abbreviated Scale of Intelligence (WASI) (Wechsler, 1999), in which
participants viewed a series of incomplete matrices and selected one of
5 multiple choice options that best completed each matrix. Total
number of correct responses was used in analyses. Verbal strategic
processing was assessed using a verbal wordlist learning task in which
participants listened to 18 words (with 3 semantic categories) then
orally recalled as many words as possible. A ratio reflecting the number
of words reported in semantic clusters relative to the total number of
words recalled over the five trials was used in analyses. Finally,
working memory was assessed using an n-back task with two conditions
(location, letter). During the task, participants either pressed a button
when the letter presented was in the same location as the letter pre-
sented two trials earlier or when the letter presented was identical to
the letter presented two trials earlier. The mean number of correct
nonresponses, averaged across location and letter conditions, was used
in analyses.
2.6. Statistical approach
Analyses were conducted in R (R Core Team, 2017) using the
package lme4 for nested modeling (Bates et al., 2015) and psych for
mediation modeling (Revelle, 2018).
2.6.1. Sample characteristics
Independent samples, Chi-squared, and Fisher Exact tests were used
to assess demographic group differences. Hierarchical linear modeling
(HLM) was used to assess group differences in intelligence quotient
(IQ), accounting for longitudinal dependencies in the data.
2.6.2. Developmental trajectories
GM and WM developmental trajectories in PKU and control groups
were analyzed using HLM. HLM is an advanced regression technique
that accounts for shared variance in hierarchically-structured (i.e.,
nested) data (Woltman et al., 2012). In the present study, timepoints
were nested within individuals. Unlike univariate analyses, HLM
Z. Hawks, et al. NeuroImage: Clinical 23 (2019) 101916
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utilizes the entire sample to optimize prediction at a given age. Thus,
the method was robust to the wide age range under study, providing
information about brain development across childhood and adolescence
without sacrificing statistical power. Age was a Level 1 variable in our
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WM dependent variables included 4 whole-brain measures (MD,
AD, RD, FA). Seven WM ROIs were also selected on the basis of prior
significant findings in cross-sectional studies of PKU (Antenor-Dorsey
et al., 2013; Hood et al., 2015; White et al., 2013). These included the
optic radiation, hippocampus, putamen, posterior-parietal occipital
cortex (PPO), corpus callosum (CC), centrum semiovale (CSO), and
prefrontal cortex WM (PFC-WM). To limit the number of comparisons,
we selected MD for ROI analyses because it has been most consistently
implicated (relative to RD, AD, and FA) in DTI studies of PKU (e.g.,
Antenor-Dorsey et al., 2013).
GM dependent variables included 4 whole-brain measures (total GM
volume, cortical GM volume, total surface area, and average cortical
thickness). Eleven GM ROIs were also selected on the basis of prior
significant findings in cross-sectional studies of PKU (e.g., putamen and
parieto-occipital lobes) (Bodner et al., 2012; Christ et al., 2016) and/or
to map onto WM ROIs (e.g., PFC structures). GM ROIs included the
dorsolateral prefrontal cortex (DLPFC), insula, caudate nucleus, pu-
tamen, nucleus accumbens, precuneus, supramarginal gyrus, superior
parietal lobule, inferior occipital gyrus, posterior transverse collateral
sulcus, and parieto-occipital sulcus.
For each WM and GM dependent variable, we ran a linear model to
examine the effects of age (grand-mean centered at 13.4 years), group,
and their cross-level (age × group) interaction. Given previous litera-
ture regarding developmental trajectories (Wierenga et al., 2014b),
quadratic and cubic effects for age were also examined. To avoid over-
fitting, preferred models were selected to minimize the Bayesian In-
formation Criterion (BIC). Holm's correction was used to adjust for
multiple comparisons (Holm, 1979).
2.6.3. Longitudinal mediation analyses
Mediation analyses examined whether brain measures influenced
the relationship between lifetime Phe exposure and executive abilities.
Specifically, we aimed to determine how relationships among these
variables may unfold over time. To this end, we required that each
participant contribute three data points to mediation models: (1) life-
time Phe exposure, calculated using all available blood Phe levels
preceding study baseline (i.e., the timepoint at which data were first
collected from that participant); (2) neuroimaging data, collected at
study baseline; and (3) executive data, collected at a visit subsequent to
study baseline. In contrast with trajectory analyses, which included all
available neuroimaging data, mediation analyses included a single
neuroimaging scan from each participant.
Mediation was implemented using a bootstrapping approach
(10,000 re-samplings), which is a non-parametric resampling procedure
for the assessment of indirect effects (Preacher and Hayes, 2008). Sig-
nificant indirect effects can occur in the absence of significant total or
direct effects. In the present analyses, the independent variable was
lifetime Phe exposure, the dependent variable was the executive abil-
ities composite, and the predicted mediators were brain measures (i.e.,
whole-brain and regional WM and GM). Variables were standardized
prior to analyses for ease of comparing mediation effects. Indirect ef-




There were no significant differences between participants with
PKU and controls with respect to age, gender, race (White vs. non-
White), or ethnicity (ps > 0.05). As is often the case in studies of PKU
(Waisbren et al., 2007), estimated IQ was significantly lower among
participants with PKU relative to controls (γ = −7.3, SE = 2.7,
p < .05).
3.2. Whole-brain analyses
We began analyses at the broadest level by examining develop-
mental trajectories of 4 whole-brain measures of average WM integrity
(MD, AD, RD, and FA) and 4 whole brain measures of GM structure
(cortical GM volume, total surface area, and average cortical thickness).
All significant results reported survived Holm's correction for multiple
comparisons. A linear model for age was consistently preferred over
quadratic and cubic models (see Supplementary Table 1).
3.2.1. WM analyses
Analyses examined the effects of age, group, and age × group on
MD, AD, RD, and FA. For 3 of 4 whole-brain WM measures (MD, RD,
FA), we found a significant main effect of age, indicating that average
MD and RD decreased whereas average FA increased as participants got
older (accounting for group and the age × group interaction; ps <
0.001). For 3 of 4 whole-brain WM measures (MD, RD, FA), we found a
significant main effect of group, indicating that participants with PKU
exhibited reduced MD and RD and increased FA compared to controls
(accounting for age and the age × group interaction; ps < 0.001). For
2 of 4 whole-brain WM measures (MD, AD), we found significant
age × group interactions (ps < 0.001), indicating that MD and AD
decreased more as a function of age in participants with PKU relative to
controls. Overall, these results indicate robust, widespread WM differ-
ences between participants with PKU and controls, such that partici-
pants with PKU have poorer WM integrity relative to controls, which
worsens as they age (see Fig. 1 and Supplementary Table 2).
3.2.2. GM analyses
Analyses examined the effects of age, group, and age × group on
total GM volume, cortical GM volume, total surface area, and average
cortical thickness. For all 4 measures of whole-brain GM, we found a
significant main effect of age, indicating that whole-brain GM de-
creased as participants got older regardless of group status (ps <
0.001). In stark contrast with our whole-brain WM results, there were
no significant effects of group or interactions between age and group for
whole-brain GM (see Fig. 2 and Supplementary Table 3).
3.3. Region of interest (ROI) analyses
As our next step, we modeled development in our 7 WM and 11 GM
ROIs. MD was used for all WM ROI analyses and volume was used for
all GM ROI analyses. ROI analyses provided specificity with respect to
the location and magnitude of neural differences between participants
with PKU and controls. All significant results reported survived Holm's
correction for multiple comparisons. A linear model for age was con-
sistently preferred over quadratic and cubic models (see Supplementary
Table 1).
3.3.1. WM analyses
Analyses examined the effects of age, group, and age × group on
MD in 7 WM ROIs. In a minority of WM ROIs (2 of 7: PPO and CSO), we
found a significant main effect of age (p < .001), indicating that MD
did not generally decrease as participants got older (accounting for
group and the age × group interaction; ps > 0.05). In 3 of 7 WM ROIs
Z. Hawks, et al. NeuroImage: Clinical 23 (2019) 101916
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(PPO, CC, and CSO), we found a significant main effect of group, in-
dicating that participants with PKU often exhibited decreased MD re-
lative to controls (accounting for age and the age × group interaction;
ps < 0.01). Finally, in a majority of WM ROIs (5 of 7: optic radiation,
hippocampus, PPO, CC, and CSO), we found significant age × group
interactions (ps < 0.01), indicating that MD decreased more as a
function of age in participants with PKU relative to controls. Overall,
results related to WM once again indicated widespread WM differences
between participants with PKU and controls (see Fig. 3 and Supple-
mentary Table 4), with worsening WM integrity as individuals with
PKU aged.
3.3.2. GM analyses
Analyses examined the effects of age, group, and age × group on
GM volume in 11 ROIs. In a majority of ROIs (8 of 11: DLPFC, caudate
nucleus, nucleus accumbens, precuneus, supramarginal gyrus, superior
parietal lobule, and parieto-occipital sulcus), we found a significant
main effect of age, indicating that ROI volume generally decreased as
participants got older regardless of group status (p < .01). Similar to
whole-brain GM results and in contrast with WM results, there were no
significant effects of group or interactions between age and group
(ps > 0.05; see Supplementary Table 5).
3.4. Mediation
Given the well-documented executive dysfunction in participants
with PKU (Araujo et al., 2009; Banerjee et al., 2011; Christ et al., 2006;
Huijbregts et al., 2013), we explored whether brain measures that
distinguished participants with PKU from controls also mediated the
relationship between lifetime Phe exposure and executive abilities in
our cohort of participants with PKU (Hood et al., 2014). To this end, we
conducted mediation analyses, focusing our analyses on WM measures
for which developmental trajectories differed between participants with
PKU and controls (i.e., significant effects of group and/or age × group;
see sections 3.2.1. and 3.3.1). No GM measures were included in
mediation analyses because none yielded significant group or
Fig. 1. Developmental trajectories of whole-brain WM integrity in participants with PKU (dotted lines) compared to controls (solid lines). Significant effects of age,
group, and age × group are denoted by asterisks (*) in the bottom left corner of each graph. Shaded bands represent 95% confidence intervals.
Fig. 2. Developmental trajectories of whole-brain GM in participants with PKU (dotted lines) compared to controls (solid lines). Significant effects of age, denoted by
asterisks (*), were consistently observed. The main effect of group and the age × group interaction never reached significance. Shaded bands represent 95%
confidence intervals.
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age × group effects.
Of the 9 mediation analyses conducted, 3 yielded statistically sig-
nificant indirect effects. Specifically, the indirect effect of lifetime Phe
exposure on executive abilities was significant for whole-brain MD
(95% CI = [−1.91, −0.04]), MD in the CC (95% CI = [−0.85,
−0.02]), and MD in the CSO (95% CI = [−1.21, −0.19]) (see
Table 2). All significant indirect effects occurred in the context of
significant direct effects (weight c′) and non-significant total effects
(weight c). These results indicated that whole-brain MD, MD in the CC,
and MD in the CSO mediate the relationship between lifetime Phe ex-
posure and executive abilities in individuals with PKU.
Fig. 3. Developmental trajectories of regional WM integrity in participants with PKU (dotted lines) compared to controls (solid lines). Significant effects of age,
group, and age × group are denoted by asterisks (*) in the bottom left corner of each graph. Shaded bands represent 95% confidence intervals.
Table 2
Whole-brain and regional WM as mediators of the relationship between lifetime Phe exposure and executive abilities.
Mediator a b c c′ Indirect effect R2
Estimate (SE) 95% CI
Whole-Brain WM
MD −0.88 (0.12)⁎ 0.92 (0.41)⁎ 0.46 (0.22) 1.27 (0.41)⁎ −0.86 (0.46) [−1.91, −0.04] 0.41
AD −0.84 (0.14)⁎ 0.40 (0.41) 0.46 (0.22) 0.80 (0.41) −0.31 (0.31) [−0.90, 0.31] 0.26
RD −0.67 (0.19)⁎ 0.43 (0.29) 0.46 (0.22) 0.75 (0.29)⁎ −0.29 (0.22) [−0.79, 0.08] 0.32
FA 0.03 (0.25) −0.18 (0.22) 0.46 (0.22) 0.47 (0.22) −0.03 (0.07) [−0.22, 0.07] 0.25
Regional WM
Optic Radiation −0.75 (0.15)⁎ −0.35 (0.32) 0.44 (0.21) 0.18 (0.32) 0.26 (0.23) [−0.17, 0.73] 0.25
Hippocampus −0.75 (0.16)⁎ 0.14 (0.32) 0.44 (0.21) 0.55 (0.32) −0.10 (0.27) [−0.62, 0.45] 0.21
PPO −0.80 (0.14)⁎ 0.21 (0.36) 0.44 (0.21) 0.61 (0.36) −0.16 (0.28) [−0.68, 0.45] 0.21
CC −0.55 (0.20)⁎ 0.43 (0.24) 0.44 (0.21) 0.68 (0.24)⁎ −0.30 (0.22) [−0.85, −0.02] 0.33
CSO −0.82 (0.13)⁎ 0.91 (0.31)⁎ 0.44 (0.21) 1.2 (0.31)⁎ −0.71 (0.25) [−1.21, −0.19] 0.47
Notes: Significant indirect effects (bolded) do not include zero within the 95% CI. SE = standard error; CI = confidence interval; WM = white matter; MD, AD, and
RD = mean, axial, and radial diffusivity, respectively; FA = fractional anisotropy; PPO = posterior parietal occipital cortex; CC = corpus callosum; CSO = centrum
semiovale.
⁎ p < .05.
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4. Discussion
The present study is the first to investigate longitudinal develop-
mental trajectories of GM in children and young adults with PKU, and it
is the first to examine trajectories of GM and WM within a single sample
of individuals with PKU. With respect to WM, results indicated wide-
spread differences between individuals with PKU and controls: in-
dividuals with PKU generally exhibited decreased MD, AD, and RD, but
increased FA. These group differences were observed at whole-brain as
well as regional-brain (ROI) levels and were frequently exacerbated by
increasing age. Notably, numerous past studies have observed little to
no difference in FA between individuals with PKU and controls (e.g.,
Antenor-Dorsey et al., 2013; Ding et al., 2008; Peng et al., 2013;
Vermathen et al., 2007; White et al., 2010). This discrepancy may be
attributable to differences in DTI processing (ROI vs. whole-brain),
study design (longitudinal vs. cross-sectional), sample characteristics
(adolescent vs. adult), and/or sample size (additional participants in-
crease statistical power to detect significant effects).
In marked contrast with WM trajectories, GM trajectories did not
differ between individuals with PKU and controls. Specifically, across
all models testing the effects of age and group on GM structures, the
main effect of group and the interaction between age and group were
never statistically significant, nor were their effect sizes appreciable.
This pattern suggests that our results cannot be accounted for by low
power and instead reflect comparable development of GM in in-
dividuals with PKU and controls. Significant main effects of age in-
dicated that, irrespective of group status, brain volume, surface area,
and cortical thickness tended to decrease as age increased, patterns that
are generally consistent with prior reports of normative brain devel-
opment (e.g., Wierenga et al., 2014b, 2014a).
To link neural substrates to treatment compliance (i.e., Phe control)
and cognitive outcome within our PKU sample, we conducted media-
tion analyses. Analyses focused on WM structures in which trajectory
analyses indicated significant effects of group and/or age × group. We
found that whole-brain MD and regional MD in the CC and CSO
mediated the relationship between Phe control and executive abilities.
These results provide empirical support for a plausible neurobiological
mechanism by which Phe control may influence cognition in in-
dividuals with PKU. Specifically, poorer Phe control may disrupt white
matter integrity, with negative consequences for executive functioning
(Anderson and Leuzzi, 2009; Christ et al., 2010; Joseph and Dyer,
2003). However, in 6 of 9 mediation analyses, we failed to observe
significant indirect effects. It is possible that our executive composite
lacked sufficient specificity to detect indirect effects relating to in-
dividual executive abilities (e.g., working memory). Indeed, prior cross-
sectional research by Hood et al. (2016) modeled distinct executive
abilities individually and identified indirect effects of MD in both the
CSO and PPO in adolescents with PKU. Alternatively, it is possible that
executive abilities are highly susceptible to recent Phe levels, in which
case a different index of Phe control (e.g., Phe measured closest to the
time of testing or mean Phe in the year prior to testing) may increase
the sensitivity of mediation analyses. In future studies, it will be of
interest to explore the time-course of relationships among Phe control,
white matter integrity, and cognition in both executive and non-ex-
ecutive domains (e.g., processing speed).
Taken together, findings from the present study indicate that PKU-
related neuropathology is more prominent in WM compared to GM
structures. This was indicated by the frequency and magnitude of group
and age × group effects in WM, as well as the consistency of null results
(for group and age × group) in GM. Although extant research has
consistently demonstrated widespread WM compromise in individuals
with PKU (Hood et al., 2015; Peng et al., 2013; Vermathen et al., 2007;
White et al., 2010), research on GM structures is more limited (Christ
et al., 2016; Pfaendner et al., 2005). The relative lack of research ne-
cessitated an exploratory (albeit hypothesis-driven) approach to GM
ROI selection in the present study. As such, we cannot rule out the
possibility that GM pathology exists elsewhere in the brain, as has been
found previously in cross-sectional analyses (Bodner et al., 2012). Nor
can we rule out the possibility that GM pathology may emerge in
adulthood, when Phe control tends to worsen and lifetime Phe exposure
tends to increase. Indeed, our sample was younger (mean
age = 13.0 years at timepoint 1) and exhibited better dietary control
(lifetime mean Phe = 399.3 μmol/L) compared to published samples in
which significant group differences in GM volume have been obtained
(e.g., mean age = 22 years, lifetime mean Phe = 610 μmol/L in Bodner
et al., 2012 and mean age = 21 years, lifetime mean Phe = 597 μmol/L
in Christ et al., 2016; Phe levels conveyed via personal communica-
tion). Lastly, the present study did not measure, and therefore cannot
speak to, potential functional differences in the GM (e.g., functional
MRI, functional connectivity MRI) between individuals with PKU and
controls. Despite having one of the largest samples of any PKU neu-
roimaging study to date, we acknowledge that we are underpowered to
completely support the null hypothesis, and fine-grained GM differ-
ences may yet exist between individuals with PKU and controls. Not-
withstanding, the magnitude of any such differences appears to pale in
comparison to the scope of WM compromise.
Finally, it is interesting to consider why WM became increasingly
compromised as individuals with PKU grew older, despite the fact that
all participants in our sample were early-and-continuously treated with
low Phe diets since infancy. PKU requires lifelong, strict adherence to
an unpalatable and complicated diet. As children with PKU progress
through adolescence and gain independence, dietary compliance often
worsens (Brown and Lichter-Konecki, 2016), which may contribute to
WM pathology. It is also possible that lasting changes in brain ma-
turation are seeded shortly after birth, prior to treatment implementa-
tion. Future lifespan studies of PKU will be necessary to disambiguate
these possibilities. Future studies will also be necessary to determine
why PKU appears to differentially effect WM and GM.
5. Conclusion
The present study was the first to assess WM and GM developmental
trajectories within a single cohort of children and young adults with
PKU. Our study yielded several important findings. First, longitudinal
analyses indicated that there was widespread WM compromise in in-
dividuals with PKU, which was exacerbated by increasing age. Second,
widespread WM compromise in PKU occurred in the absence of whole-
brain and/or regional GM pathology. Finally, WM compromise medi-
ated the relationship between treatment compliance (i.e., Phe control)
and executive abilities, suggesting a possible neural mechanism to ex-
plain the significant cognitive sequelae seen in individuals with PKU.
Our results make significant contributions to the literature regarding
neurodevelopment in PKU, as they clarify the specificity, timing, and
cognitive consequences of whole-brain and focal WM compromise.
They also contribute to a growing view emphasizing the importance of
lifelong dietary control in PKU (Hawks et al., 2018; Hood et al., 2015,
2014; Pilotto et al., 2019; Van Wegberg et al., 2017).
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